P1189: INITIAL SAFETY RUN-IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

• A. McMillan,
• C. Haioun,
• J.-M. Sancho,
• A. Viardot,
• A. Rodriguez Izquierdo,
• E. M. Donato Martin,
• A. M. García-Sancho,
• J. Sandoval-Sus,
• H. Tilly,
• E. Vandenberghe,
• J. Hirata,
• P. Choudhry,
• Y. M. Chang,
• L. Musick,
• M. Matasar

Affiliations

A. McMillan

1 Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

C. Haioun

2 Lymphoid Malignancies Unit, Groupe Hospitalier Henri Mondor, Créteil Cedex, France

J.-M. Sancho

3 ICO-HU Germans Trias I Pujol, Barcelona, Spain

A. Viardot

4 University Hospital of Ulm, Ulm, Germany

A. Rodriguez Izquierdo

5 Hospital Universitario 12 de Octubre Servicio de Hematología, Madrid

E. M. Donato Martin

6 Hospital Universitario Dr Peset Servicio de Hematología, Valencia

A. M. García-Sancho

7 Hospital Clínico Universitario de Salamanca Servicio de Hematología, Salamanca, Spain

J. Sandoval-Sus

8 Moffitt Cancer Center at Memorial Healthcare Institute, Pembroke Pines, United States of America

H. Tilly

9 Centre Henri Becquerel and University of Rouen, Rouen, France

E. Vandenberghe

10 St James Hospital Cancer Clinical Trials Office, Dublin, Ireland

J. Hirata

11 Genentech, Inc., South San Francisco, United States of America

P. Choudhry

11 Genentech, Inc., South San Francisco, United States of America

Y. M. Chang

12 Hoffmann-La Roche Ltd, Mississauga, Canada

L. Musick

11 Genentech, Inc., South San Francisco, United States of America

M. Matasar

13 Memorial Sloan Kettering Cancer Center, New York, United States of America